Brigatinib and brigatinib: dual identities of the same drug

Although the names of brigatinib and brigatinib are slightly different, they are actually two names for the same drug. Its English name is Brigatinib, and its trade name is Alunbrig. This drug is a targeted therapy designed to treat non-small cell lung cancer (NSCLC), especially in patients whose disease continues to worsen despite other treatments. Especially for NSCLC patients who carry ALK (anaplastic lymphoma kinase) gene mutations.

Brigatinib, also known as brigatinib, was developed by Ariad Pharmaceuticals, Inc. Its mechanism of action is to inhibit the activity of ALK protein, thereby curbing the proliferation and spread of tumor cells. It excels in improving patient quality of life and extending survival. But like other targeted drugs, it can cause side effects such as nausea, vomiting and diarrhea. If used in combination with anti-EGFR antibodies such as cetuximab or panitumumab, brigatinib can overcome the resistance to osimertinib caused by the EGFR C797S mutation. Therefore, patients need to be closely observed during medication.

In medicine, a drug may have multiple names due to differences in language, translation, or marketing strategies. Brigatinib and brigatinib epitomize this situation. Although the names are different, their pharmacological effects and therapeutic effects are exactly the same.

It is critical for both doctors and patients to ensure a solid understanding of the accurate naming and correct use of medications. This not only ensures that patients receive appropriate treatment, but also avoids potential risks caused by misunderstanding or confusion. Therefore, when we refer to brigatinib or brigatinib, it should be clear that they are actually the same drug and must be used strictly in accordance with medical instructions.